Eric Sanchez

1.6k total citations
78 papers, 1.2k citations indexed

About

Eric Sanchez is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Eric Sanchez has authored 78 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Hematology, 40 papers in Molecular Biology and 26 papers in Oncology. Recurrent topics in Eric Sanchez's work include Multiple Myeloma Research and Treatments (55 papers), Monoclonal and Polyclonal Antibodies Research (21 papers) and Protein Degradation and Inhibitors (15 papers). Eric Sanchez is often cited by papers focused on Multiple Myeloma Research and Treatments (55 papers), Monoclonal and Polyclonal Antibodies Research (21 papers) and Protein Degradation and Inhibitors (15 papers). Eric Sanchez collaborates with scholars based in United States, Mexico and Israel. Eric Sanchez's co-authors include James R. Berenson, Mingjie Li, Haiming Chen, Cathy S. Wang, Benjamin Bonavida, Jeffrey A. Steinberg, Cathy Wang, Regina A. Swift, Haiming Chen and George Tang and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Eric Sanchez

77 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric Sanchez United States 18 677 605 576 304 257 78 1.2k
Kaori Shinjo Japan 21 577 0.9× 323 0.5× 568 1.0× 106 0.3× 111 0.4× 51 1.1k
Kensuke Naito Japan 18 623 0.9× 308 0.5× 660 1.1× 92 0.3× 130 0.5× 51 1.2k
Yawara Kawano Japan 17 584 0.9× 406 0.7× 742 1.3× 47 0.2× 237 0.9× 67 1.2k
Lorrin Yee United States 17 134 0.2× 514 0.8× 446 0.8× 86 0.3× 217 0.8× 37 1.0k
Steffen Klippel United States 15 611 0.9× 363 0.6× 686 1.2× 35 0.1× 146 0.6× 27 1.2k
Taruna Arora India 17 103 0.2× 257 0.4× 401 0.7× 172 0.6× 269 1.0× 57 1.0k
Steven Novick United States 16 645 1.0× 437 0.7× 819 1.4× 39 0.1× 142 0.6× 28 1.4k
Jay Yang United States 18 318 0.5× 281 0.5× 810 1.4× 67 0.2× 85 0.3× 103 1.3k
Alexander Nakeff United States 17 389 0.6× 134 0.2× 326 0.6× 71 0.2× 157 0.6× 56 936
Xuehua Zhu China 18 190 0.3× 202 0.3× 519 0.9× 87 0.3× 131 0.5× 44 1.0k

Countries citing papers authored by Eric Sanchez

Since Specialization
Citations

This map shows the geographic impact of Eric Sanchez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Sanchez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Sanchez more than expected).

Fields of papers citing papers by Eric Sanchez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Sanchez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Sanchez. The network helps show where Eric Sanchez may publish in the future.

Co-authorship network of co-authors of Eric Sanchez

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Sanchez. A scholar is included among the top collaborators of Eric Sanchez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Sanchez. Eric Sanchez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sanchez, Eric, Mingjie Li, Camilia Soof, et al.. (2019). The anti-myeloma effects of the selective JAK1 inhibitor (INCB052793) alone and in combination in vitro and in vivo. Annals of Hematology. 98(3). 691–703. 13 indexed citations
2.
Maglione, Paul J., Huaibin M. Ko, Minami Tokuyama, et al.. (2019). Serum B-Cell Maturation Antigen (BCMA) Levels Differentiate Primary Antibody Deficiencies. The Journal of Allergy and Clinical Immunology In Practice. 8(1). 283–291.e1. 14 indexed citations
3.
Chen, Haiming, Mingjie Li, Eric Sanchez, et al.. (2017). Combined TRAF6 Targeting and Proteasome Blockade Has Anti-myeloma and Anti-Bone Resorptive Effects. Molecular Cancer Research. 15(5). 598–609. 18 indexed citations
4.
Li, Mingjie, Eric Sanchez, Camilia Soof, et al.. (2017). Serum Bcma May Interfere with Anti-Bcma-CAR-Transduced T Cells or Other Anti-Bcma Antibody-Based Immunotherapy in Multiple Myeloma. Blood. 130. 4413–4413. 6 indexed citations
5.
Bujarski, Sean, Kyle A. Udd, Camilia Soof, et al.. (2017). Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Multiple Myeloma Patients Undergoing New Treatments. Blood. 130. 4371–4371. 1 indexed citations
6.
7.
Sun, Clare, Camilia Soof, Sarah E. M. Herman, et al.. (2017). Serum B-Cell Maturation Antigen As a Biomarker for Chronic Lymphocytic Leukemia Treated with Ibrutinib. Blood. 130. 4031–4031. 2 indexed citations
8.
Sanchez, Eric, Mingjie Li, Cathy S. Wang, et al.. (2017). Anti-angiogenic and anti-multiple myeloma effects of oprozomib (OPZ) alone and in combination with pomalidomide (Pom) and/or dexamethasone (Dex). Leukemia Research. 57. 45–54. 11 indexed citations
9.
Li, Mingjie, Suzie Vardanyan, Nika M Harutyunyan, et al.. (2016). Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica. 102(4). 785–795. 140 indexed citations
10.
Sanchez, Eric, George Tang, Nika M Harutyunyan, et al.. (2016). Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma. Clinical Cancer Research. 22(13). 3383–3397. 87 indexed citations
11.
Pogue, Sarah, Tetsuya Taura, Mingying Bi, et al.. (2016). Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity. PLoS ONE. 11(9). e0162472–e0162472. 45 indexed citations
12.
Sanchez, Eric, Mingjie Li, Cathy S. Wang, et al.. (2016). Effects of INCB052793, a Selective JAK1 Inhibitor, in Combination with Anti-Myeloma Agents on Human Multiple Myeloma (MM) In Vitro and In Vivo. Blood. 128(22). 3297–3297. 1 indexed citations
13.
Sanchez, Eric, Haiming Chen, & James R. Berenson. (2014). In vivo models of multiple myeloma (MM). Biochemical Pharmacology. 89(3). 313–320. 2 indexed citations
14.
Chen, Haiming, Eric Sanchez, Mingjie Li, et al.. (2014). Anti-Myeloma Activity by the Combination of the JAK2 Inhibitor Ruxolitinib with Lenalidomide and Corticosteroids. Blood. 124(21). 2114–2114. 6 indexed citations
15.
Sanchez, Eric, Jing Shen, Jeffrey A. Steinberg, et al.. (2010). The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo. Leukemia Research. 35(3). 373–379. 38 indexed citations
16.
Sanchez, Eric, Mingjie Li, Jeffrey A. Steinberg, et al.. (2009). The proteasome inhibitor CEP‐18770 enhances the anti‐myeloma activity of bortezomib and melphalan. British Journal of Haematology. 148(4). 569–581. 64 indexed citations
17.
Campbell, Richard A., Eric Sanchez, Jeffrey A. Steinberg, et al.. (2009). Vorinostat enhances the antimyeloma effects of melphalan and bortezomib. European Journal Of Haematology. 84(3). 201–211. 43 indexed citations
18.
Campbell, Richard A., Eric Sanchez, Jeffrey A. Steinberg, et al.. (2007). The mTOR Inhibitor RAD001 (Everolimus) Inhibits Myeloma Tumor Growth In Vivo and Enhances the Anti-MM Effects of Bortezomib and Arsenic Trioxide.. Blood. 110(11). 4801–4801. 3 indexed citations
19.
Campbell, Richard A., Melinda S. Gordon, Eric Sanchez, et al.. (2006). The Humanized Anti-CD40 Antibody SGN-40 Inhibits Tumor Growth in LAGκ-1A, a CD40+ Mouse Model of Human Multiple Myeloma.. Blood. 108(11). 3506–3506. 3 indexed citations
20.
Cruz, J.P. De La, et al.. (1991). Effects of Dipyridamole on the Short-Term Evolution of Glomerulonephritis. ˜The œNephron journals/Nephron journals. 58(1). 13–16. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kaori Shinjo Breakdown of academic impact, for papers by Kensuke Naito Breakdown of academic impact, for papers by Yawara Kawano Breakdown of academic impact, for papers by Lorrin Yee Breakdown of academic impact, for papers by Steffen Klippel Breakdown of academic impact, for papers by Taruna Arora Breakdown of academic impact, for papers by Steven Novick Breakdown of academic impact, for papers by Jay Yang Breakdown of academic impact, for papers by Alexander Nakeff Breakdown of academic impact, for papers by Xuehua Zhu
Rankless by CCL
2026